The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated. The following will be done at 0 and 3 months: - OGTT - questionnaires about sleep and activity - Actigraph - Anthropometry - Blood pressure

NCT01705639

Conditions

1. Diabetes
2. Glucose Tolerance

Interventions

1. Drug: Melatonin

Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?. Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated.

Modern living is associated with an epidemic of type 2 diabetes mellitus (T2DM). Sleep disturbances such as insomnia or frequent awakenings are strong risk factors for T2DM with several studies indicating a central role of melatonin. Additionally, a certain single nucleotide polymorphism in the melatonin receptor gene, MTNR1B rs10830963, with an allele frequency of 30 %, is associated with increased fasting plasma glucose and T2DM. Due to treatment of, among other things, insomnia, the use of melatonin is increasing rapidly in Denmark with a 100-fold increase from 2007-2012 in children and adolescents. No previous studies have thoroughly assessed changes in glucose and fatty acid metabolism after 3 months of melatonin treatment in patients with T2DM.

NCT03859934

Conditions

1. Metabolic Disease
2. Insulin Sensitivity
3. Glucose Metabolism Disorders (Including Diabetes Mellitus)
4. Type 2 Diabetes Mellitus
5. Blood Pressure
6. Inflammation

Interventions

1. Drug: Melatonin
2. Drug: Placebo Oral Tablet

MeSH:Diabetes Mellitus Insulin Resistance Metabolic Diseases Glucose Metabolism Disorders Inflammation

HPO:Diabetes mellitus Insulin resistance

Additionally, a certain single nucleotide polymorphism in the melatonin receptor gene, MTNR1B rs10830963, with an allele frequency of 30 %, is associated with increased fasting plasma glucose and T2DM.

MTNR1a rs10830963 influence on change in insulin sensitivity and insulin secretion.

MTNR1a rs10830963 genotype influence on insulin sensitivity and insulin secretion (see outcome 1 + 2).

3. Does the MTNR1B rs10830963 risk allele alter the insulin secretion and insulin sensitivity compared with carries of the normal variant after chronic melatonin treatment?